Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DWC202211 and DWC202212 Interaction in Healthy Volunteers
NCT05699070Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of aspirin and rabeprazole in gastric ulcer and cardiovascular disease (CVD) (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration up to 27 days and Area Under the Curve to Last Quantifiable Concentration up to 27 days. Status: unknown.
02
Drugs
aspirinrabeprazole
03
Conditions
gastric ulcercardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05699070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699070.